This shop uses cookies and other technologies so that we can improve your experience on our sites.

Serrapeptase - Super Strength, 250,000 IU

Serrapeptase - Super Strength, 250,000 IU

€40.83

Dietary supplement Serrapeptase is a natural enzyme with a concentration of 250,000 IU.

Out-of-Stock


redeem
By buying this product you can collect up to 81 loyalty points . Your cart will contain total 81 points that can be converted into a voucher of €0.81 .


Serrapeptase is a natural enzyme. The Serrapeptase - Super Strength supplement is contained in the highest Natures Aid quality with a concentration of 250,000 IU.
2 month treatment / 60 tablets.
Basic description:
Serratiopeptidase with a molecular weight of approximately 52 kDa was first isolated from the enterobacterium Serratia sp. This microorganism was originally isolated in the 1960s from a silkworm larva and allows the emerging mole to dissolve its cocoon. The enzyme belongs to the group of enzymes Serralysin and is known to cleave peptides with Asn-Gln, CysSO3H-gly, Arg-Gly and Tyr-Tyr bonds, as well as a bond between His-Leu, Gly-Ala, Ala-Leu, Tryleu , Gly-Gly, Phen-Tyr and Tyr-Thr, which exhibit broad substrate specificity. The enzyme has been known in the EU since the 1980s, and several tests and studies have been carried out on it, as evidenced by the rich publishing activity (see References and studies) . Serratiopeptidase has been marketed in Europe as a variety of nutritional supplements for over 30 years.
Content of active substances in 1 tablet:

Enteric coated tablets, for safe passage through the stomach before dissolution. . Microcrystalline Cellulose, Calcium Carbonate, Di-Calcium Phosphate, Serratiopeptidase 250.000 iu , Enteric Coating (Ethylcellulose, Ammonium Hydroxide, Medium Chain Triglycerides, Oleic Acid), Lactose Monohydrate (product of milk) Sodium Carboxymethylcellulose, Anticaking Agent (Vegetable Source) Enteric Coating (Sodium Alginate, Vegetable Source Stearic Acid).

Application:
It is very important to know that Elixir Serrapeptase should be taken on an empty stomach because the capsule dissolves in the small intestine. If the capsules are taken incorrectly, they are emptied from the body with food. The capsule is taken with a sufficient amount of water. Improper use of a nutritional supplement reduces the absorption and effect of the enzyme.
  • 1 capsule daily on an empty stomach, half an hour before a meal, or two hours after a meal
The activity of the enzymes is given in IU (International Unit) and not in the weight of the contents. The highest quality is guaranteed by a value with a concentration of 250,000 IU.
Do not exceed the recommended daily dosage. Taking nutritional supplements is not a substitute for a varied healthy diet and regular exercise. Do not use this product if you are allergic or sensitive to any of its ingredients. It is not recommended for use in children under 12 years of age, pregnant or breastfeeding women.

If you suffer from any type of illness or allergy that requires medical attention, talk to your doctor before taking this medicine. Although the enzyme serrapeptase has no contraindications, people with blood clotting disorders should consult their doctor before using it, as serrapeptase causes blood thinning.
Storage:
Keep out of reach of children, in a dry and cool place.

Study references:
  1. What does Serrapeptase do? / orig. What does Serrapeptase do? /, Biomedics Labs RX, 2020/01/20
  2. True / False: Proteolytic enzymes. https://e-terapia.sk/proteolyticke-enzymy-wobenzym-serrapeptaza/
  3. Braga, PC et al. Effects of serrapeptase on muco-ciliary clearance in patients with chronic bronchitis . Curr. Ther. Res. 29 (5): 738-744, 1981.
  4. Mazzonie, A. et al. Evaluation of serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicenter, double-blind randomized trial versus placebo. J. int. Med. Res. 18 (5): 379-388, 1990.
  5. Kee WH. Tan SL, Lee V. Salmon YM. The treatment of breast engorgement with Serrapeptase (Danzen): a randomized double-blind controlled trial. Singapore Med J. 1989: 30 (1): 48-54.
  6. M izukoshi, D. et al. A double-blind clinical study of serrapeptase in the treatment of chronic sinusitis. Igaku Ayrni 109: 50-62.1979.
  7. Carratu, L. et al. Physio-chemical and rheological research on mucolytic activity of serrapeptase in chronic broncho-pneumopathies. Curr. Ther. Res. 28 (6): 937-951. 1980
  8. Kakinumu, A. et al. Regression of fibrinolysis in scalded rats by administration of serrapeptase. Biochem. Pharmacol. 31: 2861-2866,1982.
  9. Marly, M. Anti-inflammatory enzymotherapy (anti-inflammatory effects of Serrapeptase) and serrapeptase benefits: clinical results in traumatology and ENT. C RTherapeut. 3: 9-19,1985.
  10. Odagiri, J. et al. Clinical applications of serrapeptase in sinusitis. Med. Consult. New Remedy 6: 201-209, 1979.
  11. Yamazaki, J. et al. Anti-inflammatory activity of TSP, a protease produced by a strain of Serratia. Folia Pharmacol. Japan. 6 ^ 302-314,1967.
  12. Harad ~, Y. Clinical efficacy of serrapeptase on buccal swelling after radical operation for chronic sinusitis. Igaku Ayumi 123: 768-778.1982.
  13. Matsudo, A. et al. Effect of serrapeptase (Danzen) on inflammatory edema following operation for thyropid disease. Med. Consult. New Remedy 18: 171-175, 1981.
  14. Fujitani, T. et al. The effect of the anti-inflammatory agent on the transfer of antibiotics (when taken together with antibiotics, enhances the effect of antibiotics) to the maxillary sinus mucosa in chronic sinusitis. Otorhinolaryngol. Clin. North Am. 66: 557-565. 1976.
  15. Tago. T. and Mitsui, S. Effects of serrapeptase in dissolution of sputum, especially in patients with bronchial asthma. Jap. Clin. Exp. Med. 49: 222-228, 1972.
  16. Mazzonie, A. et al. Evaluation of serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicenter, double-blind randomized trial versus placebo. J. int. Med. Res. 18 (5): 379-388, 1990.
  17. Kase, Y. et al. A new method for evaluating mucolytic expectorant activity and its application. II. Application to two proteolytic enzymes, serrapeptase and seaprose. Medical Research 32: 374-378,1982.
  18. Marriott, C. Modification of the rheoloaical properties of mucus by drugs. Adv. Exp. Med. Biol. 144 ^ 75-84, 1982.
  19. Majima. Y. et al. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am. Rev. Respit. Dis. 141: 79-83.1990.
  20. Miyata, K. Intestinal absorption of serrapeptase. J ApplBiochem. 1980: 2: 111-16.
  21. Aso T. et al. Breast engorgement and its treatment: Clinical effects of Danzen (serrapeptase) an anti-inflammatory enzyme preparation. The world of Obstetrics and Gynecology (Japanese). 1981: 33: 371-9.
  22. Esch PM, Gemgross H. Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase-a prospective study (German). FortschrMed. 1989; 107 (4): 67-8, 71-2.
  23. Majima Y, lnagaki M, Hirata K. Takeuchi K, M orishita A, Sakakura Y. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol. 1988; 244 (6): 355-9.
  24. Selan L, Berlutti F, Passariello C. Comodi-Ballanti MR, Thaller MC. ? roteolytic enzymes: a new treatment strategy for prosthetic infections? Antimicrob Agents Cheroother. 1993; 37 (12): 2618-21.
  25. Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu H, Hirata M, Arai T, et al. Augmentation by serrapeptase of tissue permeation by cefotiam (Japanese). Jpn JAntibiot. 1986; 39 (3): 761-7
60 tbl., 250.000 IU

No customer reviews for the moment.